secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2026-09-28T10:30:27+00:00
Accession:  0001493152-26-044432
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Hepion Pharmaceuticals replaces Grassi with RRBB as auditor amid going-concern doubt and material weaknesses
--------------------------------------------------------------------------------

- Hepion's audit committee approved dismissing Grassi & Co., CPAs, P.C. and engaging Rosenberg Rich Baker Berman P.A. as independent auditor on Sept. 21, 2026.
- Grassi was informed on Sept. 22, 2026 of its immediate dismissal; its reports on 2025 and 2024 included an explanatory paragraph about substantial doubt over going concern.
- Hepion cited material weaknesses in internal control over financial reporting described in its 2025 and 2024 10-Ks and 10-Qs for March 31 and June 30, 2026.
- Hepion reported no disagreements with Grassi on accounting principles, disclosures, or audit scope through Sept. 21, 2026; no RRBB consultations were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226044432/0001493152-26-044432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315226044432/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer